Biopsy study during pancreatic cancer surgery to guide treatment
Part of Cancer clinical trials.
This study looks at specific body chemistry pathways in pancreatic cancer tissue to better understand what may help treatment work. If you are having pancreatic surgery, the researchers will take extra small tissue samples during the operation to study tumor and normal tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have pancreatic adenocarcinoma confirmed by biopsy
- Your doctors plan curative pancreatic surgery (with or without chemotherapy beforehand)
- You are willing to have extra small biopsies taken during surgery (about 4–6 tissue samples of tumor and nearby normal tissue)
- You can understand the study and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This study tests how well an AI tool can guide which pre-surgery treatment is best for people with pancreatic cancer that can be removed. It uses your tumor's genetic fingerprint to choose the most effective therapy.
This study looks at how tiny particles in blood (“exosomes”) carry signals between cells in people having pancreatic surgery. The goal is to understand these signals in different pancreatic conditions and treatment situations, which may help future care.
This trial studies and analyzes tissue samples from people who had surgery for exocrine pancreatic (pancreatic duct-type) cancer. It may help researchers better understand the disease biology and improve future care.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This study tracks tiny pieces of cancer DNA in your blood after pancreatic cancer surgery to see if they can predict whether cancer might come back. Researchers will draw blood several times over the next year to test this new monitoring approach.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.